| 2026-08-10 | Deck | 2Q 2026 Financial Results |
| 2026-08-10 | Press release | Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-10 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-10 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-15 | Press release | Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy |
| 2026-07-15 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-14 | Press release | Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 |
| 2026-07-07 | Press release | Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) |
| 2026-06-26 | Press release | Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) |
| 2026-06-18 | Press release | Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month |
| 2026-06-15 | Press release | Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 |
| 2026-06-09 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-04 | Press release | Axsome Therapeutics Presents New SYMBRAVO® Data at the American Headache Society (AHS) 68th Annual Scientific Meeting |
| 2026-06-03 | Press release | Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation |
| 2026-06-03 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-01 | Press release | Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month |
| 2026-05-26 | Press release | Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting |
| 2026-05-07 | Press release | Axsome Therapeutics Recognizes Mental Health Month |
| 2026-05-05 | Press release | Axsome Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-05-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-04 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-01 | Deck | Investor Overview |
| 2026-05-01 | Press release | Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader |
| 2026-04-30 | Press release | Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease |
| 2026-04-30 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-01 | Press release | Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions |
| 2026-04-01 | 8-K | Form 8-K, Item 8.01 |
| 2026-02-25 | Press release | Axsome Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-02-24 | Press release | Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms |
| 2026-02-23 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-23 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-23 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-18 | Press release | Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2026-02-17 | 8-K | Form 8-K, Item 8.01 |
| 2026-01-15 | Press release | Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia |
| 2026-01-12 | Press release | Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |